Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Cantor Fitzgerald Starts Fermi (FRMI) at Overweight
-
Core Scientific Inc. (CORZ) PT Raised to $26 at Cantor Fitzgerald: Risk/Reward Attractive
-
Cantor Fitzgerald Reiterates Kinsale Capital (KNSL) at Neutral Rating; Results 'Not Good Enough'
-
Cantor Fitzgerald Raises Essential Properties Realty Trust (EPRT) PT to $36: Sees 2026 Beats, Raises
-
Molina Healthcare (MOH) PT Lowered to $180 at Cantor Fitzgerald: '26 Outlook Cautious
-
Cantor Fitzgerald Reiterates Intel (INTC) at Neutral: Wants to See 'Improvement in Fundamentals'
-
Cantor Fitzgerald Reiterates Coursera Inc (COUR) at Overweight: Consumer Segment Execution Healthy
-
Varonis Systems (VRNS) PT Raised to $70 at Cantor Fitzgerald on Good Execution Through SaaS Transition
-
Cantor Fitzgerald Reiterates JFrog (FROG) at Overweight: 'Bullish Heading into 3Q25 Earnings'
-
Cantor Fitzgerald Assumes Novavax (NVAX) at Overweight
-
Orchid Island Capital Announces Third Quarter 2025 Results
-
Cantor Fitzgerald Reiterates Overweight Rating on Goosehead Insurance Inc. (GSHD)
-
Cantor Fitzgerald Reiterates Overweight Rating on Lam Research (LRCX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Tenable (TENB)
-
Cantor Fitzgerald Reiterates Overweight Rating on BankUnited (BKU)
-
Viking Therapeutic (VKTX) PT Raised to $105 at Cantor Fitzgerald
-
Tesla (TSLA) PT Raised to $510 at Cantor Fitzgerald
-
Tango Therapeutics raises $225 million in stock offering
-
Tango Therapeutics Announces $225 Million Financing
-
Fossil extends exchange offer deadline after falling short of minimum threshold
-
Fossil extends exchange offer for senior notes after missing 90% threshold
-
Fossil Announces Intention to Proceed with the UK Proceeding and Extension of Exchange Offer for Its Senior Notes
-
Electra secures $82 million to fund North America's first cobalt refinery
-
Electra Completes Financing and Debt Restructuring, Fully Funding North America’s First Cobalt Sulfate Refinery
-
Cantor Fitzgerald Reiterates Elevance (ELV) at Overweight: Cautious of '26 Medicaid Environment
-
Cantor Fitzgerald Reiterates Chubb Corporation (CB) at Neutral; Notes Group in Strong Relative Place
-
Cantor Fitzgerald Raises CACI International (CACI) PT to $675 Ahead of F1Q26 Earnings
-
Cantor Fitzgerald Reiterates Texas Instruments (TXN) at Neutral After 3Q Beat, 4Q Guidance Miss
-
Cantor Fitzgerald Reiterates Ardelyx, Inc (ARDX) at Overweight on Expected Ibsrela Upside
-
Cantor Fitzgerald Reiterates Alnylam Pharmaceuticals (ALNY) at Neutral on Good Execution
-
Cantor Fitzgerald Reiterates Fortinet (FTNT) at Neutral: Investment Stance Unchanged into 3Q25
-
Cantor Fitzgerald Reiterates Checkpoint Software (CHKP) at Neutral; Constructive on Long-Term Outlook
-
Tesla set for strong quarter fueled by rush to get expiring US EV tax credits
-
Cantor Fitzgerald Downgrades Alector Inc. (ALEC) to Neutral
-
Cantor Fitzgerald Reiterates Cytokinetics (CYTK) at Overweight Post Model Update
-
Cantor Fitzgerald Starts Nuscale Power (SMR) at Overweight, 'Only NRC-Approved Advanced Nuclear Player'
-
Cantor Fitzgerald Reiterates Overweight Rating on W.R. Berkley (WRB) Ahead of Q3 Earnings
-
Cantor Fitzgerald Reiterates Overweight Rating on Tesla (TSLA) Ahead of Q3 Earnings
-
Cantor Fitzgerald Starts Sui Group (SUIG) at Overweight
-
Cantor Fitzgerald Starts Kyivstar Group (KYIV) at Overweight
-
Form 13F-HR CANTOR FITZGERALD INVEST For: Sep 30
-
Disc Medicine prices $250 million stock offering at $84 per share
-
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
-
Lexeo Therapeutics closes $153.8 million public offering and private placement
-
Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering
-
Investor behind Zions, Western Alliance bad loans is tied to $270 million in troubled debt
-
Cantor Fitzgerald Reiterates Overweight Rating on Microsoft (MSFT) as Windows 10 Support Ends
-
Cantor Fitzgerald Starts Kodiak AI (KDK) at Overweight
-
Regan Total Return Income Fund (RCIRX) Celebrates Five-Year Anniversary
-
Cantor Fitzgerald Reiterates Overweight Rating on Varonis Systems (VRNS) After AI Identity Protection Launch

